Your browser doesn't support javascript.
Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
Koerber, Nina; Priller, Alina; Yazici, Sarah; Bauer, Tanja; Cheng, Cho-Chin; Mijocevic, Hrvoje; Wintersteller, Hannah; Jeske, Samuel; Vogel, Emanuel; Feuerherd, Martin; Tinnefeld, Kathrin; Winter, Christof; Ruland, Jürgen; Gerhard, Markus; Haller, Bernhard; Christa, Catharina; Zelger, Otto; Roggendorf, Hedwig; Halle, Martin; Erber, Johanna; Lingor, Paul; Keppler, Oliver; Zehn, Dietmar; Protzer, Ulrike; Knolle, Percy A.
  • Koerber N; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Priller A; Institute of Molecular Immunology and Experimental Oncology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Yazici S; Institute of Molecular Immunology and Experimental Oncology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Bauer T; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Cheng CC; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Mijocevic H; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Wintersteller H; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Jeske S; Institute of Molecular Immunology and Experimental Oncology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Vogel E; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Feuerherd M; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Tinnefeld K; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Winter C; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Ruland J; Institute of Clinical Chemistry, Technical University of Munich, School of Medicine, Munich, Germany.
  • Gerhard M; Institute of Clinical Chemistry, Technical University of Munich, School of Medicine, Munich, Germany.
  • Haller B; Institute of Medical Microbiology, Immunology and Hygiene, Technical University of Munich, School of Medicine, Munich, Germany.
  • Christa C; Institute of Medical Informatics, Statistics and Epidemiology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Zelger O; Institute of Virology, Helmholtz-Zentrum München/Technical University of Munich, School of Medicine, Munich, Germany.
  • Roggendorf H; Institute of Sports Medicine, Technical University of Munich, School of Medicine, Munich, Germany.
  • Halle M; Institute of Molecular Immunology and Experimental Oncology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Erber J; Institute of Sports Medicine, Technical University of Munich, School of Medicine, Munich, Germany.
  • Lingor P; Department of Internal Medicine II, Technical University of Munich, School of Medicine, Munich, Germany.
  • Keppler O; Department of Neurology, Technical University of Munich, School of Medicine, Munich, Germany.
  • Zehn D; German Center for Infection Research (DZIF), Munich partner site, Munich, Germany.
  • Protzer U; Max von Pettenkofer Institute & Gene Center, Department of Virology, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Knolle PA; Institute of Animal Physiology and Immunology, Technical University of Munich, School of Life Sciences, Munich, Germany.
Nat Commun ; 13(1): 153, 2022 01 10.
Article in English | MEDLINE | ID: covidwho-1616980
ABSTRACT
Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after BNT162b2 mRNA-vaccination in convalescents after asymptomatic or mild SARS-CoV-2 infection. Virus-specific and virus-neutralizing antibody titers rapidly declined in convalescents over 9 months after infection, whereas virus-specific cytokine-producing polyfunctional T cells persisted, among which IL-2-producing T cells correlated with virus-neutralizing antibody titers. Among convalescents, 5% of individuals failed to mount long-lasting immunity after infection and showed a delayed response to vaccination compared to 1% of naïve vaccinees, but successfully responded to prime/boost vaccination. During the follow-up period, 8% of convalescents showed a selective increase in virus-neutralizing antibody titers without accompanying increased frequencies of circulating SARS-CoV-2-specific T cells. The same convalescents, however, responded to vaccination with simultaneous increase in antibody and T cell immunity revealing the strength of mRNA-vaccination to increase virus-specific immunity in convalescents.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Convalescence / Nucleocapsid / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Cohort study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-021-27649-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Convalescence / Nucleocapsid / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Cohort study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-021-27649-y